Producers shown on SFDA

Producers shown on EP

Staff size:About 7000 persons

Registered capital:RMB 1 billion 492 million

Producer:Zhuhai Rundu Pharmaceutical Co., Ltd. is a modern scientific and technological pharmaceutical enterprise integrating drug R & D, production and sales. It is located in Jinwan District, Zhuhai City, Guangdong Province. It was established in 1999. The company has a sound quality management system and has established a drug production and manufacturing center in strict accordance with the national GMP requirements. The existing product production lines (including APIs, tablets, capsules, preparation intermediates (pellets), etc.) have passed the new national GMP certification, and some characteristic API products have passed the official certification of the World Health Organization, the European Union and Japan, Some products have passed the on-site inspection of FDA.

Staff size:About 1500 persons

Registered capital:RMB 185.7 million

Producer:Zhejiang Tianyu Pharmaceutical Co., Ltd. founded in 2003, is headquartered in Taizhou, Zhejiang, with a registered capital of more than 180 million yuan. It has six wholly-owned subsidiaries and more than 3800 employees. Tianyu Co., Ltd. is a joint-stock pharmaceutical enterprise specializing in R & D, manufacturing and sales of APIs and advanced pharmaceutical intermediates. It was successfully listed on Shenzhen Stock Exchange on September 19, 2017 (Stock Code: 300702). The company is a national high-tech enterprise, an innovative pilot enterprise in Zhejiang Province and a patent demonstration enterprise in Zhejiang Province. It has established a provincial enterprise research institute, a provincial high-tech enterprise research and development center, a provincial innovation carrier, a provincial enterprise technology center and a provincial postdoctoral research workstation. The company's main products include antihypertensive, hypoglycemic, antithrombotic and antiasthmatic drug raw materials and intermediates. It is one of the world's major manufacturers of cardiovascular raw materials, and its products sell well in markets at home and abroad.

Staff size:About 3800 persons

Registered capital:RMB 180 million

Producer:Zhejiang Menovo Pharmaceutical Co., Ltd. was established in November, 2005. It's a hi-tech enterprise supported by China, located in Zhejiang Hangzhou Bay Shangyu Economic and Technological Development Zone (national level), in the three metropolitan center position of Shanghai, Hangzhou and Ningbo, and near Jiashao bridge. It is the one of the core API production bases of Menovo. 

Staff size:600-699 persons

Registered capital:USD 6.681081 million

Mainly manufacturing chemical Active Pharmaceutical Ingredients(APIs), including Valsartan, Isoniazid, Nicotinamide, etc., which are all main manufacturer in China, and sold well to the United States, EU, Southeast Asia and over dozens of countries and areas. Identified as National High-tech Enterprise, with advanced instruments and equipments, a good quality management system with many times passed FDA cGMP inspections, WHO PQ inspections, etc.

Staff size:About 400 persons

Registered capital:RMB 80.12 million

Producer:Shangyao Kony (Changzhou) Pharmaceutical Co., Ltd. is located in Jiangnan Water Township and the shore of Taihu Lake, covering an area of 65000 square meters, fixed assets of more than 50 million yuan and more than 240 employees, including scientific and technological personnel, accounting for 20%. Its nucleoside antiviral raw materials and intermediates, sartan antihypertensive raw materials and intermediates have a large output and a wide variety in China.

The company organizes production in strict accordance with GMP, has complete production and scientific research equipment, has a number of imported advanced testing equipment, has stable product quality, is exported to Southeast Asia and developed countries and regions, and enjoys a high reputation among customers at home and abroad.

Staff size:About 240 persons

Registered capital:RMB 14.94638 million

Producer:Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. was restructured and established by the former Zhuzhou Xiangjiang pharmaceutical factory in 1998. It is a holding subsidiary of the listed company "Qianjin pharmaceutical". The registered capital is 48 million yuan. The company's main products include 19 varieties such as lamivudine tablets, valsartan capsules and enalapril maleate tablets. At present, the company has 13 invention patents, 10 utility model patents, 28 design patents, 43 registered trademarks and more than 50 drug production approvals“ The two trademarks of Xiangjiang and Jianganling were rated as "famous trademarks of Hunan Province".

Staff size:1000-1999 persons

Registered capital:RMB 48 million

Producer:Changzhou Siyao Pharmaceutical Co., Ltd. has passed the three management system certification of national drug GMP, international environmental management ISO14001 and international occupational health and safety OHSMS18001, and three products have passed the certification of FDA and CEP of the European Union.

Current production capacity: 25 raw material intermediates, 100 tons, of which 50 tons are self exported; 20 million lyophilized powder needles and 100 million water needles; 2 billion capsules, tablets and controlled and sustained release preparations; 20 million creams and new transdermal patches.

Registered capital:USD 7.08 million